Assembly Biosciences (NASDAQ:ASMB) Price Target Raised to $38.00 at SVB Leerink

Assembly Biosciences (NASDAQ:ASMB) had its price target raised by SVB Leerink from $36.00 to $38.00 in a research report sent to investors on Wednesday, BenzingaRatingsTable reports. SVB Leerink currently has an outperform rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. William Blair reissued a buy rating on shares of Assembly Biosciences in a report on Thursday, June 25th. ValuEngine cut shares of Assembly Biosciences from a buy rating to a hold rating in a research note on Thursday, July 2nd. Zacks Investment Research lowered Assembly Biosciences from a buy rating to a hold rating in a research note on Tuesday, June 23rd. Mizuho reiterated a buy rating and set a $30.00 target price on shares of Assembly Biosciences in a research report on Friday, May 8th. Finally, BidaskClub raised Assembly Biosciences from a buy rating to a strong-buy rating in a report on Friday, June 26th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and an average target price of $39.40.

NASDAQ ASMB opened at $23.02 on Wednesday. Assembly Biosciences has a 1-year low of $8.13 and a 1-year high of $25.45. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.14 and a quick ratio of 12.14. The business’s fifty day moving average price is $21.75 and its 200-day moving average price is $19.07.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.22. The company had revenue of $4.08 million during the quarter, compared to analysts’ expectations of $3.82 million. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%. Research analysts anticipate that Assembly Biosciences will post -2.98 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its holdings in Assembly Biosciences by 188.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 8,620 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 5,633 shares during the period. Franklin Resources Inc. purchased a new position in shares of Assembly Biosciences in the fourth quarter valued at about $14,829,000. BlackRock Inc. lifted its position in shares of Assembly Biosciences by 15.6% in the first quarter. BlackRock Inc. now owns 2,297,866 shares of the biopharmaceutical company’s stock valued at $34,079,000 after acquiring an additional 310,648 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in shares of Assembly Biosciences in the first quarter worth about $266,000. Finally, Geode Capital Management LLC raised its stake in Assembly Biosciences by 21.8% during the 1st quarter. Geode Capital Management LLC now owns 413,809 shares of the biopharmaceutical company’s stock valued at $6,136,000 after purchasing an additional 74,163 shares during the period. Hedge funds and other institutional investors own 88.34% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: Day Trading

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.